# HM17321: Roche’s 2.3 Billion Dollar Bet on Preserving Muscle During Weight Loss Update — August 31, 2026 HM17321 is no longer the only corticotropin-releasing factor receptor programme in the obesity pipeline. Neurocrine Biosciences has disclosed **NBIP-’2118** , a CRF2 receptor agonist now in Phase 1, alongside its GLP-1/GIP/glucagon triple agonist [NBIP-’1968](https://portaltowellness.net/research/nbip-1968-triple-agonist-obesity/) , which entered first-in-human testing in August 2026. Two sponsors pursuing the same receptor family is the point at which a mechanism stops being one company’s isolated bet — but neither Neurocrine compound has published human data either, so the evidence position described below for HM17321 is unchanged. Evidence & Research Status Evidence LevelPreclinical / Early-Stage Research FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption Last UpdatedAugust 25, 2026 What This Article Covers On 24 August 2026, Hanmi Pharmaceutical announced that Genentech had licensed worldwide rights outside South Korea to an experimental obesity compound called HM17321. The headline figure was large… Primary References [ClinicalTrials.gov NCT07219589](https://clinicaltrials.gov/study/NCT07219589) [MedCity News](https://medcitynews.com/2026/08/roche-hanmi-obesity-ucn2-crf2-peptide-drug-lean-mass-preserve-muscle-rhhby/) [Fierce Biotech](https://www.fiercebiotech.com/biotech/roche-pens-25b-pact-hanmis-clinical-stage-obesity-drug-targeting-less-used-mechanism) Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use. Development stage HM17321 (LA-UCN2) - Preclinical - Phase 1 - Phase 2 - Phase 3 - Regulatory review - Approved What has been shown in humans? Nothing yet. A Phase 1 study is evaluating safety, tolerability and pharmacokinetics in approximately 90 healthy and obese participants. Reduced fat mass and preserved or increased lean mass have been reported only in rodent and non-human primate studies. Sponsor: Hanmi Pharmaceutical. Worldwide rights outside South Korea licensed to Genentech, a member of the Roche Group, in August 2026. Portal to Wellness does not sell this compound. Accurate as of 25 August 2026. [ClinicalTrials.gov NCT07219589](https://clinicaltrials.gov/study/NCT07219589) On 24 August 2026, Hanmi Pharmaceutical announced that Genentech had licensed worldwide rights outside South Korea to an experimental obesity compound called HM17321. The headline figure was large: 190 million dollars upfront, and up to roughly 2.3 billion dollars in total including development, regulatory and commercial milestones, plus tiered royalties. The number is not the interesting part. What makes this deal worth reading closely is the mechanism Roche paid for, and what it signals about where obesity research is heading. HM17321 is not another incretin. It is a peptide aimed at a different question entirely: not how much weight comes off, but what kind of tissue it comes from. ## What HM17321 Is — and What It Is Not HM17321, also referred to as LA-UCN2, is a long-acting analog of urocortin-2. Urocortin-2 is a naturally occurring peptide in the corticotropin-releasing factor family. The compound is designed to selectively activate the CRF2 receptor. It is not a [GLP-1 receptor](https://portaltowellness.net/glossary-glp-1-receptor/) agonist. It is not a dual or triple incretin agonist. It does not share a mechanism with [semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) , [tirzepatide](https://portaltowellness.net/shop/tirzepatide-60mg/) or retatrutide. Hanmi describes it as a non-incretin candidate, and that distinction is the entire point of the programme. It is also not a product. HM17321 is an investigational compound in Phase 1 trials. It has no marketing authorisation anywhere, it is not available for purchase from any source, and it is not sold by Portal to Wellness. ## The Mechanism: UCN2 and the CRF2 Receptor CRF2 receptors are found in the central nervous system and, relevant here, in skeletal muscle. The working hypothesis behind HM17321 is that activating CRF2 in muscle tissue produces a different body-composition outcome than suppressing appetite does. Incretin-based compounds reduce body weight substantially through mechanisms that include reduced energy intake. When intake falls sharply, the body draws on both fat and lean tissue. That is ordinary physiology, not a flaw specific to any one drug, and it is well documented in the caloric-restriction literature generally. A CRF2-directed approach is attempting to change which tissue is lost. Whether it does so in humans is an open question that the current trial is not designed to answer. ## What the Preclinical Data Reported The most instructive finding in the published preclinical material is also the most easily misread. In diet-induced obese mice, HM17321 produced *less total weight loss* than [semaglutide](https://portaltowellness.net/research/semaglutide-research-guide/) , but *greater fat-mass loss* . Lean-mass preservation was also reported in obese rhesus monkeys. Read that comparison carefully, because it inverts the usual framing. On a scale, the [semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) animals would have looked like the better result. On a body-composition analysis, they did not. The two measurements disagreed. These are animal findings, largely company-reported. Rodent and primate body-composition results have a long history of not reproducing in humans, and no conclusion about people should be drawn from them. ## Why Weight Lost and Fat Lost Are Not the Same Number Body weight is a single figure that combines fat mass, lean mass, bone, glycogen and water. Two interventions can produce identical numbers on a scale while producing quite different underlying compositions. Lean mass is not synonymous with muscle. Lean body mass, as measured by DXA and similar methods, includes organs, connective tissue and body water alongside skeletal muscle. A reported change in lean mass is therefore not a direct measurement of muscle tissue, and consumer bioimpedance devices are considerably less reliable again. This distinction gets lost routinely in secondary coverage. The scientific interest in HM17321 and compounds like it rests on this gap. If a mechanism can shift the ratio of fat loss to lean loss, that is a different kind of result than simply producing a larger total. ## What Phase 1 Is Actually Testing The registered Phase 1 study is a randomised, double-blind, placebo-controlled single and multiple ascending dose trial in approximately 90 healthy and obese participants. Its stated measures are safety, tolerability, pharmacokinetics and pharmacodynamics. Phase 1 asks whether a compound can be administered safely and what the body does to it. It is not designed or powered to demonstrate that participants lose more fat or retain more muscle. Under the terms of the licensing agreement, Hanmi completes Phase 1 and Genentech assumes development from Phase 2 onward, which places any meaningful human efficacy readout years away. ## What a 2.3 Billion Dollar Deal Does and Does Not Prove A licensing agreement of this size means a large pharmaceutical company assessed the science and the commercial opportunity and decided both were worth substantial capital at risk. That is a genuine signal about how the field is thinking. It is not clinical evidence. Deal value reflects expected value across a range of outcomes, most of which involve the compound failing. Large licensing deals for candidates that later failed in Phase 2 or Phase 3 are common enough to be unremarkable. The current evidence position for HM17321 is straightforward: - **Preclinical efficacy:** reported and encouraging, in animals. - **Human safety:** under evaluation in Phase 1. - **Human efficacy:** not established. Anyone presenting HM17321 as a muscle-preserving weight-loss treatment has moved several steps ahead of the data. ## Open Questions - Does CRF2 activation alter body composition in humans, or only in rodents and primates? - What is the tolerability profile of sustained CRF2 agonism, given the receptor family involvement in stress signalling? - Is lean-mass preservation observed by DXA, or only inferred from total-weight and fat-mass arithmetic? - Does any effect persist beyond the period of active weight loss? - Hanmi has suggested combination potential with incretin therapy. Is that supported by anything beyond mechanism-level reasoning? ## Why This Belongs on a Watchlist The competitive question in obesity development is broadening. For several years the differentiator was the magnitude of total weight reduction. The Roche transaction, alongside other non-incretin approaches now entering development, suggests the next differentiator may be the composition of that reduction, along with tolerability and combination potential. That shift matters for how research literature in this category should be read. Total weight change alone is becoming a less informative endpoint, and studies that report body composition separately are becoming more useful than those that do not. ## Watching this one HM17321 is in Phase 1 and is not available from any research supplier, including us — a licensing deal is not a product. What we can do is track it. If you want to be told when a compound on our watchlist becomes available to source, or you have a different compound you would like us to look at, tell us on our [compound request page](https://portaltowellness.net/request-compound/) . Nothing is charged and nothing is committed on either side. ### Continue Your Research - [Muscle preservation during caloric restriction: what the research shows](https://portaltowellness.net/research/muscle-preservation-caloric-restriction-research/) - [Body recomposition and GLP-1 research](https://portaltowellness.net/research/body-recomposition-glp1-research/) - [TOFA and ACC inhibition: another non-incretin metabolic mechanism](https://portaltowellness.net/research/tofa-research-acc-inhibition/) **Sources:** Hanmi Pharmaceutical press release, 24 August 2026; [ClinicalTrials.gov NCT07219589](https://clinicaltrials.gov/study/NCT07219589) ; [MedCity News](https://medcitynews.com/2026/08/roche-hanmi-obesity-ucn2-crf2-peptide-drug-lean-mass-preserve-muscle-rhhby/) ; [Fierce Biotech](https://www.fiercebiotech.com/biotech/roche-pens-25b-pact-hanmis-clinical-stage-obesity-drug-targeting-less-used-mechanism) . Reported deal values differ between outlets; the figures above follow Hanmi’s own announcement. *HM17321 is not sold by Portal to Wellness and is not available for purchase here. It is an investigational compound in early clinical development. Compounds that Portal to Wellness does offer are supplied for laboratory research use only and are not for human or veterinary use. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.* --- Source: https://portaltowellness.net/research/hm17321-muscle-preservation-obesity-research/ Research use only. Terms: https://portaltowellness.net/research-use-only/